We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




New Radioactive Agents for Colon Cancer Work Inside Cells

By Biotechdaily staff writers
Posted on 23 Oct 2007
Researchers have developed a potentially novel way to fight colorectal cancer utilizing tiny molecules to deliver potent barrages of radiation inside cancer cells, unlike existing treatments that bind to the surface of cells and attack from the outside and cause unwanted side effects. More...


In laboratory studies with normal and cancer cells, the new radiation delivery system proved able to precisely target colon cancer cells, and what remains is likely to be easily filtered out by the kidneys because the delivery system's molecules are so small.

As reported in the October 3, 2007, issue of the journal PLoS One, Johns Hopkins University (Baltimore, MD, USA) colorectal cancer specialists John Abraham, Ph.D., and Stephen Meltzer, M.D., working with the theory that small molecules typically make better treatment vehicles--designed small pieces of protein, only 10 amino acids long as the foundation for their drugs. By contrast, antibodies used to deliver radiation or chemicals can be over 1,000 amino acids long.

The team attached radioactive phosphorous, P32, as a test of how well their peptides worked and "to our surprise, our first tests showed that cells were ingesting these molecules, thus transferring the radiation inside and killing them by breaking up their DNA and proteins,” Dr. Abraham said.

While cautioning that the new radiation delivery system is still far from ready for use in humans, Dr. Abraham noted that P32 gives off high energy that can penetrate through 5-mm of human tissue, making it a good candidate for fighting colon cancer since colon cancer cells can frequently form large, thick tumors into which drugs may not penetrate very well. Moreover, P32-labeled peptides may serve another valuable use: to find small metastases or recurrences of colon tumors while they are still small enough to treat. Images of the body can be taken of the labeled peptides as they bind, revealing where stray tumor cells may be nesting.

The investigators then designed and evaluated a variety of P32-peptides on 18 normal and cancerous human cell samples. The most potent peptide, MA5, was shown to be able to bind to adenocarcinoma cells, which make up 95% of all colon cancers, 150 times more strongly than other cell types and be delivered inside cells within two hours.


Related Links:
Johns Hopkins University

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Platelet Function Analyzer
PL-12
Gold Member
Platelet Function Analyzer
AGGRENG-40
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

UK Project Advances Blood-Based Dementia Testing Toward Routine Clinical Care

Dementia is the leading cause of death in the UK, accounting for almost one in eight deaths, with more than 72,000 people dying from dementia, including Alzheimer’s disease, in 2025. Despite this burden,... Read more

Microbiology

view channel
Image: Overview of a rapid diagnostic workflow for fungal bloodstream infections (Photo courtesy of Professor Hiroki Takahashi and IMO, Chiba University, Japan)

Genomic Workflow Identifies Fungal Pathogens Before Blood Cultures Turn Positive

Fungal bloodstream infections pose a major threat to hospitalized patients. Candida species cause most invasive fungal infections worldwide and are among the leading causes of hospital-acquired bloodstream... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.